Selective Hippocampal Subfield Atrophy Mediates Cognitive Decline in Cushing's Disease
Brain and Behavior · 2025
DOI: 10.1002/brb3.71030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Zhebin Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hippocampus, Pituitary ACTH Hypersecretion, Cognitive Dysfunction. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Young Talent Project of Chinese PLA General Hospital, National Natural Science Foundation of China, National Science and Technology Major Project of the Ministry of Science and Technology of China.
Abstract (Originalsprache)
Background
Cushing's disease (CD) provides insight into how prolonged high cortisol exposure affects brain structure. While CD patients show cognitive and emotional symptoms linked to hippocampal function and detailed analysis of hippocampal subfield changes remains limited.
Methods
The study included 91 patients with active CD and 53 matched healthy controls who underwent T1‐weighted magnetic resonance imaging and comprehensive neuropsychological assessment. We employed voxel‐based morphometry, automated segmentation, and shape analysis to evaluate gray matter volume, subfield volumes, and hippocampal morphology. Clinical correlations of hippocampal subfield volumes were also explored.
Results
Compared to controls, CD patients showed decreased hippocampal gray matter volume, particularly in the body and tail regions. Specific subfields, including presubiculum‐body, subiculum‐body, CA4‐body, and granule cell layer, showed significant volume reductions. Shape analysis revealed corresponding surface alterations. Notably, left CA4‐body and left GC‐ML‐DG‐body volumes mediated the relationship between cortisol levels and cognitive performance.
Conclusions
CD patients exhibit distinct patterns of hippocampal atrophy affecting specific subfields, with changes correlating to hormone levels and cognitive symptoms. These structural alterations may serve as potential biomarkers for CD and provide insight into the mechanisms underlying cognitive dysfunction in hypercortisolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Neurosurgery, Chinese PLA 942 Hospital, Yinchuan, Ningxia, China.
- Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Department of Neurosurgery, Xiong'an Xuanwu Hospital, Xiong'an New Area, Hebei, China.
- Department of Radiotherapy, Beijing Tiantan Hospital Capital Medical University, Beijing, China.
- Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
ORCID-Profile: Yanyang Zhang
Förderung
- Young Talent Project of Chinese PLA General Hospital
- National Natural Science Foundation of China
- National Science and Technology Major Project of the Ministry of Science and Technology of China
Zitieren
APA
Feng, Z., Zhou, T., Yan, X., He, K., Liu, H., Yu, X., Lu, R., Ma, Z., Yu, X., & Zhang, Y. (2025). Selective Hippocampal Subfield Atrophy Mediates Cognitive Decline in Cushing's Disease. Brain and Behavior. https://doi.org/10.1002/brb3.71030
Vancouver
Feng Z, Zhou T, Yan X, He K, Liu H, Yu X, et al. Selective Hippocampal Subfield Atrophy Mediates Cognitive Decline in Cushing's Disease. Brain and Behavior. 2025. doi:10.1002/brb3.71030
BibTeX
@article{Feng2025,
author = {Feng, Zhebin and Zhou, Tao and Yan, Xinyuan and He, Kunyu and Liu, Hailong and Yu, Xiaoteng and Lu, Rong and Ma, Zhiguo and Yu, Xinguang and Zhang, Yanyang},
title = {Selective Hippocampal Subfield Atrophy Mediates Cognitive Decline in Cushing's Disease},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.71030}
}
EUVIMED